Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06489028 · ClinicalTrials.gov registry record · Phase 3

Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Therapy-resistant CVU (Phase III)

A Phase 3 study of Venous Leg Ulcer, sponsored by RHEACELL GmbH & Co. KG.

Active
Registry status
Phase 3
Development phase
250
Enrollment target
15
Study locations

NCT06489028: Active Phase 3 study of Venous Leg Ulcer, sponsored by RHEACELL GmbH & Co. KG.

NCT06489028 is a Phase 3 study of Venous Leg Ulcer that is active but no longer recruiting, run by RHEACELL GmbH & Co. KG. The registered enrollment target is 250 participants, roughly in line with the 238-participant average among 35 other Venous Leg Ulcer trials with a reported enrollment target. The trial reports 15 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06489028, a Phase 3 study of Venous Leg Ulcer, is active but no longer recruiting, sponsored by RHEACELL GmbH & Co. KG.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
250 participants
Enrollment target
15
Study locations

Study Summary

The aim of this clinical trial is to investigate the efficacy and safety of allo-APZ2-CVU, administered topically on therapy-resistant non-healing CVUs compared to placebo.

Primary Outcome

Complete wound closure already persisting for at least two weeks

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG allo-APZ2-CVU

Study Locations (15)

Other

  • RHEACELL Clinical Trial Site - Multiple Locations
  • RHEACELL Clinical Trial Site - Multiple Locations
  • RHEACELL Clinical Trial Site - Multiple Locations
  • RHEACELL Clinical Trial Site - Several Locations
  • RHEACELL Clinical Trial Site - Multiple Locations
  • RHEACELL Clinical Trial Site - Multiple Locations
  • RHEACELL Clinical Trial Site - Multiple Locations
  • RHEACELL Clinical Trial Site - Multiple Locations
  • RHEACELL Clinical Trial Site - Multiple Locations
  • RHEACELL Clinical Trial Site - Multiple Locations
  • RHEACELL Clinical Trial Site - Multiple Locations

Florida

  • RHEACELL Clinical Trial Site - Hialeah
  • RHEACELL Clinical Trial Site - Miami

Massachusetts

  • RHEACELL Clinical Trial Site - Boston

Minnesota

  • RHEACELL Clinical Trial Site - Minneapolis

Trial Details

FieldValue
Enrollment Target 250 participants
Start Date 2024-12-26
Est. Completion 2027-09
Phase Phase 3
RHEACELL GmbH & Co. KG

3 total trials

What the registry record for NCT06489028 still lists

NCT06489028 is an interventional study that assigns participants to a tested intervention. The registered 250 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 238-participant average among 35 other Venous Leg Ulcer trials with a reported enrollment target.

The record links to 1 condition, with Venous Leg Ulcer appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06489028 lists 15 locations in 4 states (Other, Florida, Massachusetts).

Frequently Asked Questions

What is clinical trial NCT06489028 about?

NCT06489028 is a clinical study titled "Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Therapy-resistant CVU (Phase III)". The aim of this clinical trial is to investigate the efficacy and safety of allo-APZ2-CVU, administered topically on therapy-resistant non-healing CVUs compared to placebo.

What is the current status of trial NCT06489028?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 250 participants. The study started on 2024-12-26. Estimated completion is 2027-09.

What conditions does trial NCT06489028 study?

This clinical trial studies the following conditions: Venous Leg Ulcer.

What interventions are being tested in trial NCT06489028?

The interventions under investigation include: Placebo (DRUG), allo-APZ2-CVU (DRUG).

Who is sponsoring clinical trial NCT06489028?

This trial is sponsored by RHEACELL GmbH & Co. KG, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06489028 being conducted?

This trial has 15 study locations across Florida, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Venous Leg Ulcer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06489028's enrollment target sits among peer trials

250 10th of 35 higher than 26 of 35 other Venous Leg Ulcer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Venous Leg Ulcer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00483249 · 250 participants · NA

    Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm

  • NCT00777712 · 250 participants

    Mechanisms Underlying Impaired Diabetic Wound Healing

  • NCT01451502 · 250 participants · NA

    Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units

  • NCT01771718 · 250 participants

    Pilot Study on In-vivo Non-invasive Skin Imaging Using Multiphoton Microscopy

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06489028, the US trial registry maintained by the National Library of Medicine. NCT06489028 (mid enrollment · multi site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.